Catalog No.
Product Name
Application
Product Information
Citations
-
SOS1 activator
VUBI1 (SOS1 Activator 1) is a benzimidazole-derived small molecule that acts as a potent activator of the guanine nucleotide exchange factor SOS1, with a dissociation constant (Kᴅ) of 44 nM. It promotes RAS activation by enhancing RAS-GTP formation and modulates downstream ERK phosphorylation, thereby influencing RAS–MAPK signaling. In addition, VUBI1 serves as a functional ligand for the development of PROTAC-based degraders, such as PROTAC SOS1 Degrader-1, to induce targeted SOS1 degradation. VUBI1 is a valuable compound for studying RAS pathway regulation and its role in cancer biology. -
Ligands for Target Protein for PROTAC
CBP/p300 ligand 10 is a selective ligand for the CBP/p300 proteins, facilitating their targeted degradation. This compound serves as a valuable component for the development of PROTACs, specifically enabling the synthesis of CBP/p300 Degrader-2. Its utility in research applications includes studies focused on cellular signaling pathways and potential therapeutic interventions in diseases associated with dysregulated CBP/p300 activity. -
Ligands for Target Protein for PROTAC
Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH is a ligand specifically designed for EZH2, functioning as a key component in PROTAC technology by recruiting E3 ligases. This compound demonstrates potential biological activity in targeted protein degradation, particularly in the context of lymphoma research. Its unique structure allows for the exploration of novel therapeutic strategies aimed at modulating EZH2 activity and its downstream effects in cancer biology. -
Ligands for Target Protein for PROTAC Chemical
PROTAC BRD4 ligand-2 is a specific ligand for the BRD4 protein, designed for use in PROTAC-mediated degradation strategies. This compound facilitates the targeted degradation of BRD4, a key regulator of transcription and associated with various cancers, by recruiting the E3 ubiquitin ligase. It is instrumental in research applications aimed at understanding BRD4's role in oncogenesis and therapeutic development in cancer treatments. -
SMARCA2/4 Ligand
SMARCA2/4-ligand-5 is a selective ligand targeting the SMARCA2 and SMARCA4 proteins, functioning as a crucial component in the PROTAC SMARCA2/4 degrader-37. This compound demonstrates potent biological activity, achieving an IC50 of ≤0.1 μM, making it suitable for applications in targeted protein degradation studies. Research utilizing SMARCA2/4-ligand-5 contributes to understanding the roles of these chromatin remodelers in various biological processes and cancer biology. -
Ligand of BRAF
BRAF ligand-1 acts as a specific ligand for the BRAF protein, playing a crucial role in the regulation of cell signaling pathways associated with cell proliferation, survival, and differentiation. This compound is important for studying the BRAF signaling pathway and its implications in various cancers. Additionally, BRAF ligand-1 can be utilized in the synthesis of CST905, further enhancing its utility in biochemical research and drug discovery efforts targeting mutant BRAF. -
Ligands for Target Protein for PROTAC
Androgen Receptor Ligand 2 acts as a ligand for the androgen receptor, facilitating the targeted degradation of this protein through the PROTAC (proteolysis-targeting chimera) mechanism. This compound is integral for the synthesis of the PROTAC Androgen Receptor Degrader-1, enabling researchers to probe the functional role of the androgen receptor in various biological contexts. Its application extends to studies in cancer research and hormone-related disorders, where modulation of androgen receptor activity may serve as a therapeutic strategy. -
Ligands for Target Protein for PROTAC
SMARCA-BD ligand 1 for PROTAC hydrochloride is a selective ligand that specifically targets the BAF ATPase subunit SMARCA2. This compound facilitates the degradation of SMARCA2 through the PROTAC mechanism, making it a valuable tool for research into protein degradation pathways and epigenetic regulation. Its applications extend to studies on cancer biology and the development of targeted therapeutic strategies. -
Ligands for Target Protein for PROTAC
SMARCA-BD ligand 1 for PROTAC dihydrochloride is a selective ligand targeting the BAF ATPase subunit SMARCA2. This compound facilitates the proteolytic degradation of SMARCA2 through the PROTAC mechanism, thereby modulating its biological activity. It is utilized in research applications focused on the regulation of chromatin remodeling and exploring therapeutic avenues for diseases associated with altered SMARCA2 function. -
SMARCA2 Ligand
SMARCA2 ligand-11 is a specific ligand for the chromatin remodeling factor SMARCA2, facilitating the development of PROTACs such as SMARCA2 degrader-32. This compound is instrumental in research applications focused on targeted protein degradation, particularly in studies aimed at elucidating the role of SMARCA2 in various biological processes and diseases. Its ability to selectively engage with SMARCA2 allows for investigations into novel therapeutic strategies in cancer and other conditions where SMARCA2 activity is implicated. -
Ligands for Target Protein for PROTAC
POI ligand-2 is a specific ligand for the GPX4 protein, facilitating targeted protein degradation. This compound is instrumental in the synthesis of PROTACs, including PROTAC GPX4 degrader-5. Its application in protein research enables efficient modulation of GPX4 levels, aiding studies in mechanistic biology and therapeutic interventions targeting oxidative stress pathways. -
Ligands for Target Protein for PROTAC
FN-1501-propionic acid is a ligand targeting cyclin-dependent kinases 2 and 9 (CDK2/9), utilized in the development of PROTAC (proteolysis targeting chimeras) for targeted protein degradation. This compound can be combined with a CRBN ligand to facilitate the design of PROTAC-based CDK2/9 degraders, enabling selective degradation of these kinases. Its application in research enhances the study of cellular processes regulated by CDK2 and CDK9, making it a valuable tool for investigating therapeutic strategies against diseases associated with dysregulated kinase activity. -
CDK9 Degrader/Ligands for Target Protein for PROTAC
(R)-PROTAC CDK9 ligand-1 is a potent degrader targeting cyclin-dependent kinase 9 (CDK9), a key regulator of transcription and cell cycle progression. This compound facilitates the synthesis of PROTACs (proteolysis-targeting chimeras), which exhibit antitumor activity by promoting the degradation of CDK9. Research applications include investigations into cancer biology and therapeutic strategies aimed at modulating CDK9 levels for improved treatment outcomes. -
Ligands for Target Protein for PROTAC
PD0325901-O-C2-dioxolane is a derivative of the MEK inhibitor PD0325901, designed as a ligand for targeted protein degradation in conjunction with VHL or CRBN E3 ligases. This compound facilitates the synthesis of MEK1/2 degraders, enabling the selective degradation of MEK proteins in experimental studies. Its application in research provides critical insights into MEK-related signaling pathways and their role in various diseases, particularly in cancer biology. -
Ligand for Target Protein for PROTAC
PROTAC SOS1 ligand 1 is a high-affinity ligand for the SOS1 protein, facilitating targeted protein degradation through PROTAC technology. This compound is instrumental in the development of therapeutic strategies by enabling the selective modulation of SOS1, which plays a pivotal role in various oncogenic signaling pathways. Researchers can utilize this reagent in studies focused on cancer biology and drug discovery, particularly in exploring novel approaches to target and degrade specific proteins associated with tumor progression. -
Intermediate
7α,25-Dihydroxycholesterol intermediate-1 is a crucial synthetic intermediate in the production of 7α,25-Dihydroxycholesterol. This compound functions as a ligand for the orphan G protein-coupled receptor EBI2 (GPR183), playing a significant role in immune system regulation and cellular signaling pathways. Its applications extend to the development of PROTACs, enabling targeted protein degradation in research and therapeutic contexts. -
Ligands for Target Protein for PROTAC
Thalidomide-5-piperazine is a ligand designed for protein-targeted degradation utilizing the PROTAC technology. This compound facilitates the recruitment of E3 ubiquitin ligases to specific target proteins, promoting their ubiquitination and subsequent proteasomal degradation. It is primarily used in research applications focused on studying protein function and modulation within cellular pathways. -
Ligands for Target Protein for PROTAC
Palbociclib-propargyl is a selective ligand for CDK6, designed for use in PROTAC applications. This compound functions through a PEG linker to effectively bind to the CRBN ligand, forming the PROTAC CP-10, which exhibits a DC50 of 2.1 nM for CDK6. Additionally, Palbociclib-propargyl features an alkyne group making it suitable for click chemistry, specifically allowing for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-bearing molecules. This reagent is valuable for advancing research in targeted protein degradation and cancer therapeutics. -
Ligands for Target Protein for PROTAC
(S)-SKBG-1 is a covalent ligand designed for targeting specific proteins in the context of PROTAC applications. Though classified as inactive, it serves an essential role as an assay control to help validate experimental conditions and results. This compound is valuable for researchers investigating the mechanisms of protein degradation and the development of targeted therapeutic strategies. -
Ligands for Target Protein for PROTAC
Tazemetostat de(methyl morpholine)-COOH is a ligand specifically designed for the target protein EZH2, facilitating the synthesis of EZH2 degraders for the PROTAC approach. This compound exhibits significant biological activity by effectively inhibiting cell viability in diffuse large B-cell lymphoma (DLBCL) and various lymphoma subtypes. It serves as a valuable tool for researchers investigating targeted protein degradation and its therapeutic potential in oncology. -
Ligands for Target Protein for PROTAC
PROTAC BRD9-binding moiety 1 hydrochloride is a ligand that selectively binds to the bromodomain protein BRD9, facilitating its targeted degradation through the PROTAC (Proteolysis Targeting Chimeras) mechanism. This compound is instrumental in research focusing on protein degradation pathways and the modulation of BRD9-associated functions in various biological contexts, such as cancer and inflammation. It serves as a valuable tool for studying the therapeutic potential of targeting BRD9 in disease models. -
Ligands for Target Protein for PROTAC
Piperidine-GNE-049-N-Boc is a ligand that targets the dCBP-1 protein, facilitating the development of proteolysis-targeting chimeras (PROTACs). This compound serves as a potent and selective heterobifunctional degrader for the transcriptional co-activators p300 and CBP. It is applicable in research aimed at understanding protein degradation mechanisms and the modulation of gene expression. -
Ligands for Target Protein for PROTAC
Demethyl-RSL3 functions as a ligand for targeted protein degradation through the proteolysis targeting chimera (PROTAC) mechanism. This compound effectively modulates cellular pathways by inducing degradation of specific proteins. Its applications lie primarily in cancer research and the development of novel therapeutic strategies aimed at improving targeted protein degradation efficacy. -
Ligands for Target Protein for PROTAC Chemical
PROTAC CDK9 ligand-1 is a potent ligand for cyclin-dependent kinase 9 (CDK9), facilitating the synthesis of PROTAC (proteolysis-targeting chimera) constructs. This compound is instrumental for targeted protein degradation studies, enabling researchers to modulate CDK9 activity and investigate its role in transcription regulation and cancer biology. PROTAC CDK9 ligand-1 supports the development of innovative therapeutic strategies aimed at selectively degrading unwanted or malfunctioning proteins. -
Ligands for Target Protein for PROTACs
PRMT5 ligand 2 is a selective ligand targeting protein arginine methyltransferase 5 (PRMT5) for use in PROTAC (proteolysis-targeting chimeras) applications. This compound facilitates the targeted degradation of PRMT5, enabling researchers to investigate its role in various cellular processes, including gene regulation and cell signaling. PRMT5 ligand 2 serves as an essential tool for studying PRMT5's biological functions and elucidating potential therapeutic targets in cancer and other diseases. -
Ligands for Target Protein for PROTAC
BMS-1166-N-piperidine-COOH is a ligand designed to target E3 ligase for PROTAC applications. This compound serves as a key component in the synthesis of PD-1/PD-L1 degrader-1, which facilitates the degradation of the PD-1/PD-L1 complex, a crucial immune checkpoint. With a potent PD-1/PD-L1 interaction inhibition demonstrated by an IC50 of 1.4 nM, BMS-1166-N-piperidine-COOH effectively reverses the suppressive effects of the PD-1/PD-L1 pathway on T cell activation, making it valuable for cancer immunotherapy research. -
Ligands for Target Protein for PROTAC
PROTAC IRAK4 ligand-1 is a synthetic ligand specifically designed to target interleukin-1 receptor-associated kinase 4 (IRAK4). This compound plays a critical role in the development of PROTAC IRAK4 degrader-1, facilitating targeted protein degradation. Its primary applications include cancer research and studies investigating inflammatory pathways, making it a valuable tool for researchers exploring IRAK4-related signaling mechanisms. -
Ligands for Target Protein for PROTAC
A-1210477-piperazinyl is a ligand that specifically binds to myeloid cell leukemia 1 (MCL1), serving as a crucial component in PROTAC (proteolysis-targeting chimeras) technology. This compound plays a significant role in targeted protein degradation research, enabling the modulation of MCL1 levels in various cellular contexts. A-1210477-piperazinyl is valuable for studies aimed at understanding MCL1's involvement in cell survival and cancer biology. -
Ligands for Target Protein for PROTAC
CDK2 ligand-2 is a selective ligand targeting cyclin-dependent kinase 2 (CDK2), facilitating the synthesis of PROTAC (proteolysis targeting chimera) molecules. By combining CDK2 ligand-2 with E3 Ligase Ligand-linker Conjugate 184, researchers can create CDK2 degrader 2, a potent tool for targeted protein degradation studies. This compound is valuable for investigating CDK2's role in cell cycle regulation and exploring therapeutic strategies in cancer research. -
Ligands for Target Protein for PROTAC
AR Antagonist 14 is a potent ligand for specific target proteins utilized in PROTAC (Proteolysis Targeting Chimeras) applications. This compound facilitates the development of targeted protein degraders, allowing for the selective degradation of androgen receptors. AR Antagonist 14 can be effectively combined with VH 101-amide-piperidine-Pip-alkyne to synthesize PROTAC degraders, enhancing research on targeted therapies in cancer and other diseases. -
Ligands for Target Protein for PROTAC
KAL-21404358 is a ligand designed for specific binding to target proteins for use in PROTAC (Proteolysis Targeting Chimeras) applications. This compound facilitates the targeted degradation of proteins, providing valuable insights into protein function and regulation. Research applications include the study of protein-protein interactions and the development of targeted therapies in cancer and other diseases. KAL-21404358 supports the advancement of innovative approaches in drug discovery and biological research. -
Ligands for Target Protein for PROTAC
PTPN2 ligand 1 is a specific ligand designed for the PTPN2 target protein, facilitating the development of PROTAC (proteolysis-targeting chimeras). This compound plays a crucial role in research applications focused on targeted protein degradation, providing researchers with the means to investigate the functional relevance of PTPN2 in various biological processes. Additionally, it serves as a synthetic precursor for the compound PVD-06, contributing to further studies in protein modulation. -
Ligands for Target Protein for PROTACs
Palbociclib-CH2COOH is a ligand designed for the Target Protein in PROTAC applications. This compound can function as an active control for evaluating the target protein ligand interactions of CPD-39 and CPD-10. Its specificity and binding capacity make it a valuable tool for researchers investigating targeted protein degradation and related pathways. -
Ligands for Target Protein for PROTAC
PXR Ligand 3 is a ligand for the Pregnane X Receptor (PXR), acting as a critical component in the development of PROTAC (Proteolysis Targeting Chimera) molecules. It facilitates the recruitment of E3 ubiquitin ligases, thereby promoting targeted degradation of specific proteins. This compound is valuable in drug discovery and biochemical research, particularly in studies focused on the modulation of PXR activity and the development of PROTAC-based therapeutics. -
Ligands for Target Protein for PROTACs
IRAK4 ligand-12 is a ligand for interleukin-1 receptor-associated kinase 4 (IRAK4), designed for use in PROTAC (proteolysis targeting chimeras) applications. This compound plays a critical role in the selective degradation of IRAK4, thus enabling the modulation of immune response pathways. It is particularly useful in research focused on inflammation and cancer, facilitating studies on targeted protein degradation strategies. IRAK4 ligand-12 can also be utilized in the synthesis of KTX-951, contributing to advancements in therapeutic development. -
Ligands for Target Protein for PROTAC
SHP2 ligand-3 is a ligand specifically designed for the SHP2 target protein, facilitating the synthesis of SHP2 protein degrader-1. This compound serves as an essential tool in targeted protein degradation studies, enabling the selective degradation of SHP2. Its application in PROTAC technology allows researchers to investigate the functional roles of SHP2 in cellular processes and disease mechanisms, supporting drug discovery and development efforts. -
Ligands for Target Protein for PROTAC
BCN-sulfonamide-PEG2-sulfonamide-N-bis(ethanol) serves as a versatile ligand for target proteins in PROTAC applications. This compound incorporates a sulfonamide linker designed to enhance the solubility of linker-conjugates. It is particularly useful in the synthesis of PROTACs aimed at inducing targeted degradation of proteins with potential antitumor activity. -
Ligands for Target Protein for PROTAC
SMARCA2/4-ligand-6 is a small molecule ligand specific for the SMARCA2 and SMARCA4 proteins, facilitating targeted protein degradation via the PROTAC (Proteolysis Targeting Chimeras) technology. This compound can be utilized in the development of PROTACs aimed at studying the roles of these epigenetic regulators in cancer biology and other diseases. SMARCA2/4-ligand-6 is a valuable tool for researchers investigating targeted therapeutic strategies and protein homeostasis. -
Ligands for Target Protein for PROTAC
BTK-IN-39 is a ligand targeting Bruton’s tyrosine kinase (BTK), designed for the synthesis of PROTAC BTK Degrader-11. This compound enables the selective degradation of BTK, facilitating studies on its biological functions and role in disease models, particularly in hematological malignancies. Its application in PROTAC technology allows for innovative approaches to therapeutic intervention by modulating protein levels within cells. -
Ligands for Target Protein for PROTAC
HDAC8-IN-11 is a potent inhibitor of histone deacetylase 8 (HDAC8), a key regulator of gene expression and cellular processes. This compound demonstrates significant biological activity by modulating acetylation levels of histones and non-histone proteins. HDAC8-IN-11 is primarily utilized in research applications focused on targeted protein degradation via PROTAC technology, facilitating the selective degradation of specific proteins in cellular models. -
Ligands for Target Protein for PROTAC
HG-7-85-01-Decyclopropane is a ligand for target proteins utilized in the PROTAC (Proteolysis Targeting Chimera) technology. This compound features the ABL inhibitor moiety and binds to IAP (inhibitor of apoptosis protein) ligands through a linker, enabling the targeted degradation of specific proteins within cells. Its application in research includes elucidating protein function and pathway regulation, making it a valuable tool in cancer biology and therapeutic development. -
Ligands for Target Protein for PROTAC
mTOR ligand 1 is a potent ligand targeting the mechanistic target of rapamycin (mTOR) for use in PROTAC (Proteolysis Targeting Chimera) applications. This compound plays a crucial role in the degradation of mTOR through the ubiquitin-proteasome system, enabling selective modulation of mTOR activity. mTOR ligand 1 is ideal for research involving mTOR signaling pathways and related cellular processes, providing a valuable tool for investigating therapeutic strategies in cancer and metabolic disorders. -
Ligands for Target Protein for PROTAC
SMARCA2/4-ligand-4 acts as a ligand for the SMARCA2 and SMARCA4 proteins, serving as an essential component for the development of Proteolysis Targeting Chimeras (PROTACs). This compound facilitates the targeted degradation of proteins associated with various cellular processes, providing a powerful tool for drug discovery and therapeutic research. SMARCA2/4-ligand-4 is integral to the synthesis of PROTAC SMARCA2/4 degrader-36, enabling investigations into the modulation of oncogenic pathways and protein homeostasis. -
Ligands for Target Protein for PROTAC
Multi Kinase Ligand 4 is a selective ligand designed for the synthesis of PROTACs, specifically PROTAC DB-0646. This compound plays a crucial role in modulating protein degradation pathways, facilitating targeted protein degradation through the ubiquitin-proteasome system. Its applications extend to drug discovery and development in cancer research, enabling investigations into the regulation of kinase activity and potential therapeutic interventions. -
Ligands for Target Protein for PROTAC
SMARCA2 ligand-7 is a specific ligand for SMARCA2, a key protein involved in chromatin remodeling. This compound is designed for use in PROTAC (PROteolysis TArgeting Chimeras) studies, facilitating targeted protein degradation. SMARCA2 ligand-7 enables researchers to investigate the functional roles of SMARCA2 in cellular processes and its potential as a therapeutic target in various diseases. -
Ligands for Target Protein for PROTAC
Demethyl-RSL3-boc is a ligand designed for targeted protein degradation through PROTAC (Proteolysis Targeting Chimeras) technology. This compound effectively interacts with target proteins to facilitate their ubiquitin-mediated degradation, thereby modulating cellular pathways. Demethyl-RSL3-boc is utilized in research applications focused on studying protein dynamics and developing novel therapeutic strategies for various diseases, including cancer. -
Ligands for Target Protein for PROTAC
SMARCA2/4-ligand-1 is a selective ligand for the proteins SMARCA2 and SMARCA4, facilitating targeted protein degradation via PROTAC (Proteolysis Targeting Chimeras) technology. This compound exhibits promising biological activity by promoting the ubquitination and subsequent degradation of these target proteins. It is designed for use in research applications focusing on gene regulation, chromatin remodeling, and the study of protein homeostasis. -
Ligands for Target Protein for PROTAC
SMARCA2 ligand-6 is a selective ligand for the SMARCA2 protein, functioning within the context of proteolysis-targeting chimera (PROTAC) technology. This compound facilitates the targeted degradation of SMARCA2, enabling researchers to study its biological functions and roles in various cellular processes. It is a valuable tool for investigating therapeutic strategies in cancer and other diseases linked to dysregulation of chromatin remodeling factors. -
Ligands for Target Protein for PROTAC
LC3B ligand 1 is a specific ligand for the target protein utilized in PROTAC technology. It plays a crucial role in synthesizing PROTAC CDK9 autophagic degrader 1, facilitating targeted protein degradation through autophagy. This compound is valuable in studies aimed at investigating protein turnover, cellular homeostasis, and the potential therapeutic applications of PROTACs in cancer and other diseases. -
SMARCA2 Ligand
SMARCA2 ligand-8 acts as a selective ligand for the target protein SMARCA2, facilitating the synthesis of the PROTAC SMARCA2/4-degrader-35. This compound is instrumental in research applications focused on targeted protein degradation, offering insights into the modulation of gene regulation and chromatin remodeling. Its utility in developing innovative degraders highlights its significance in the study of cancer biology and potential therapeutic interventions.
